# Manuel Posada

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6401852/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 175 papers | 4,998 citations | 134610 34 h-index | 156644 58 g-index |
| 203 all docs | 203 docs citations | 203 times ranked | 6663 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Toxic oil syndrome: health-related quality-of-life assessment using the SF-36 Health Survey. International Journal of Epidemiology, 2022, 51, 491-500. | 0.9 | 4 |
| 2 | The RDâ€Connect Genomeâ€Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases. Human Mutation, 2022, , . | 1.1 | 18 |
| 3 | A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain. Scientific Reports, 2022, 12, 3750. | 1.6 | 3 |
| 4 | Determinants of satisfaction with the detection process of autism in Europe: Results from the ASDEU study. Autism, 2022, 26, 2136-2150. | 2.4 | 3 |
| 5 | Diagnostic Process in Rare Diseases: Determinants Associated with Diagnostic Delay. International Journal of Environmental Research and Public Health, 2022, 19, 6456. | 1.2 | 24 |
| 6 | Transcultural Validation of a Spanish Version of the Quality of Life in Epidermolysis Bullosa Questionnaire. International Journal of Environmental Research and Public Health, 2022, 19, 7059. | 1.2 | 5 |
| 7 | The ASDEU autism prevalence study in northern Spain. European Child and Adolescent Psychiatry, 2021, 30, 579-589. | 2.8 | 21 |
| 8 | Early non-social behavioural indicators of autism spectrum disorder (ASD) in siblings at elevated likelihood for ASD: a systematic review. European Child and Adolescent Psychiatry, 2021, 30, 497-538. | 2.8 | 30 |
| 9 | De novo small deletion affecting transcription start site of short isoform of <scp>AUTS2</scp> gene in a patient with syndromic neurodevelopmental defects. American Journal of Medical Genetics, Part A, 2021, 185, 877-883. | 0.7 | 5 |
| 10 | Real-World Experiences in Autistic Adult Diagnostic Services and Post-diagnostic Support and Alignment with Services Guidelines: Results from the ASDEU Study. Journal of Autism and Developmental Disorders, 2021, 51, 4129-4146. | 1.7 | 20 |
| 11 | El trastorno del espectro autista en la UniÃ³n Europea (ASDEU). Siglo Cero, 2021, 52, 43-59. | 0.2 | 0 |
| 12 | Effect of a Focused Social and Communication Intervention on Preterm Children with ASD: A Pilot Study. Journal of Autism and Developmental Disorders, 2021, , 1. | 1.7 | 2 |
| 13 | Progress, challenges and global approaches to rare diseases. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2711-2716. | 0.7 | 37 |
| 14 | Spanish Cultural Validation of the Modified Checklist for Autism in Toddlers, Revised. Journal of Autism and Developmental Disorders, 2020, 50, 2412-2423. | 1.7 | 26 |
| 15 | Early Detection, Diagnosis and Intervention Services for Young Children with Autism Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives. Journal of Autism and Developmental Disorders, 2020, 50, 3380-3394. | 1.7 | 41 |
| 16 | A call for global action for rare diseases in Africa. Nature Genetics, 2020, 52, 21-26. | 9.4 | 31 |
| 17 | Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease. Hepatology International, 2020, 14, 127-137. | 1.9 | 44 |
| 18 | Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotypeâ€“phenotype relationships. Journal of Human Genetics, 2020, 65, 165-174. | 1.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The case for open science: rare diseases. JAMIA Open, 2020, 3, 472-486. | 1.0 | 33 |
| 20 | Explaining Age at Autism Spectrum Diagnosis in Children with Migrant and Non-Migrant Background in Austria. Brain Sciences, 2020, 10, 448. | 1.1 | 7 |
| 21 | Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity. Journal of Molecular Diagnostics, 2020, 22, 1205-1215. | 1.2 | 14 |
| 22 | Efficacy of focused social and communication intervention practices for young children with autism spectrum disorder: A meta-analysis. Early Childhood Research Quarterly, 2020, 51, 430-445. | 1.6 | 15 |
| 23 | Towards Harmonized Biobanking for Biomonitoring: A Comparison of Human Biomonitoring-Related and Clinical Biorepositories. Biopreservation and Biobanking, 2020, 18, 122-135. | 0.5 | 13 |
| 24 | Nuevas perspectivas sobre el Problema de la Unidad Espacial Modificable (PUEM) en relaciÃ³n con la representaciÃ³n cartogrÃ¡fica de enfermedades raras. Investigaciones GeogrÃ¡ficas, 2020, , 71. | 0.3 | 0 |
| 25 | Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain. Expert Opinion on Orphan Drugs, 2019, 7, 363-372. | 0.5 | 6 |
| 26 | Temporal and Cartographic Analyses of the Distribution within Spain of Mortality Due to Granulomatosis with Polyangiitis (1984â€“2016). International Journal of Environmental Research and Public Health, 2019, 16, 1388. | 1.2 | 0 |
| 27 | Tetralogy of Fallot in Spain: a nationwide registry-based mortality study across 36â€‰years. Orphanet Journal of Rare Diseases, 2019, 14, 79. | 1.2 | 6 |
| 28 | Spanish multidisciplinary clinical practice guideline on Anderson-Fabry disease in adults: A live guideline. Molecular Genetics and Metabolism, 2019, 126, S97-S98. | 0.5 | 0 |
| 29 | A Review of International Biobanks and Networks: Success Factors and Key Benchmarksâ€”A 10-Year Retrospective Review. Biopreservation and Biobanking, 2019, 17, 512-519. | 0.5 | 10 |
| 30 | Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations. International Journal of Environmental Research and Public Health, 2019, 16, 119. | 1.2 | 8 |
| 31 | The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. European Journal of Human Genetics, 2018, 26, 631-643. | 1.4 | 33 |
| 32 | Building a theoretical framework for autism spectrum disorders screening instruments in Europe. Child and Adolescent Mental Health, 2018, 23, 359-367. | 1.8 | 3 |
| 33 | Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney and Blood Pressure Research, 2018, 43, 406-421. | 0.9 | 35 |
| 34 | Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 706-716. | 1.4 | 24 |
| 35 | Geographic Analysis of Motor Neuron Disease Mortality and Heavy Metals Released to Rivers in Spain. International Journal of Environmental Research and Public Health, 2018, 15, 2522. | 1.2 | 19 |
| 36 | A Nationwide Registry-Based Study on Mortality Due to Rare Congenital Anomalies. International Journal of Environmental Research and Public Health, 2018, 15, 1715. | 1.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Recommendations for Improving the Quality of Rare Disease Registries. International Journal of Environmental Research and Public Health, 2018, 15, 1644. | 1.2 | 116 |
| 38 | SpainUDP: The Spanish Undiagnosed Rare Diseases Program. International Journal of Environmental Research and Public Health, 2018, 15, 1746. | 1.2 | 19 |
| 39 | Short-Term Effects of Ozone on Mortality: Comparative Analysis of Urban and Suburban Zones in Madrid (Spain). Journal of Health Science (El Monte), 2018, 6, . | 0.1 | 0 |
| 40 | PReFiNe project: strategic plan to improve knowledge & recognition of Fabry disease among Spanish nephrologists. Molecular Genetics and Metabolism, 2017, 120, S41. | 0.5 | 1 |
| 41 | Data Quality in Rare Diseases Registries. Advances in Experimental Medicine and Biology, 2017, 1031, 149-164. | 0.8 | 56 |
| 42 | Mortality Statistics and their Contribution to Improving the Knowledge of Rare Diseases Epidemiology: The Example of Hereditary Ataxia in Europe. Advances in Experimental Medicine and Biology, 2017, 1031, 521-533. | 0.8 | 6 |
| 43 | Rare Disease Biospecimens and Patient Registries: Interoperability for Research Promotion, a European Example: EuroBioBank and SpainRDR-BioNER. Advances in Experimental Medicine and Biology, 2017, 1031, 141-147. | 0.8 | 3 |
| 44 | Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data. Advances in Experimental Medicine and Biology, 2017, 1031, 3-21. | 0.8 | 19 |
| 45 | Preparing for the Future of Rare Diseases. Advances in Experimental Medicine and Biology, 2017, 1031, 641-648. | 0.8 | 32 |
| 46 | Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework. Advances in Experimental Medicine and Biology, 2017, 1031, 55-94. | 0.8 | 20 |
| 47 | Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. Journal of Neuromuscular Diseases, 2017, 4, 293-306. | 1.1 | 125 |
| 48 | Congenital Anomalies: Cluster Detection and Investigation. Advances in Experimental Medicine and Biology, 2017, 1031, 535-557. | 0.8 | 1 |
| 49 | Early Detection and Intervention of ASD: A European Overview. Brain Sciences, 2017, 7, 159. | 1.1 | 34 |
| 50 | Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer. BioMed Research International, 2017, 2017, 1-13. | 0.9 | 28 |
| 51 | Impact of rare diseases in oral health. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2016, 21, 0-0. | 0.7 | 12 |
| 52 | Patient participation in the development of a clinical guideline for inherited retinal dystrophies. Expert Opinion on Orphan Drugs, 2016, 4, 691-697. | 0.5 | 6 |
| 53 | The risk of re-identification versus the need to identify individuals in rare disease research. European Journal of Human Genetics, 2016, 24, 1553-1558. | 1.4 | 46 |
| 54 | Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. European Journal of Health Economics, 2016, 17, 31-42. | 1.4 | 50 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Social/economic costs and health-related quality of life in patients with scleroderma in Europe. European Journal of Health Economics, 2016, 17, 109-117. | 1.4 | 28 |
| 56 | Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. European Journal of Health Economics, 2016, 17, 19-29. | 1.4 | 59 |
| 57 | The Quality of Rare Disease Registries: Evaluation and Characterization. Public Health Genomics, 2016, 19, 108-115. | 0.6 | 16 |
| 58 | Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. European Journal of Health Economics, 2016, 17, 99-108. | 1.4 | 31 |
| 59 | Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. European Journal of Health Economics, 2016, 17, 79-87. | 1.4 | 40 |
| 60 | Social/economic costs and quality of life in patients with haemophilia in Europe. European Journal of Health Economics, 2016, 17, 53-65. | 1.4 | 53 |
| 61 | Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. European Journal of Health Economics, 2016, 17, 7-18. | 1.4 | 38 |
| 62 | Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. European Journal of Health Economics, 2016, 17, 67-78. | 1.4 | 16 |
| 63 | Overview of existing initiatives to develop and improve access and data sharing in rare disease registries and biobanks worldwide. Expert Opinion on Orphan Drugs, 2016, 4, 729-739. | 0.5 | 6 |
| 64 | Characterization of Immune Cell Phenotypes in Adults with Autism Spectrum Disorders. Journal of Investigative Medicine, 2016, 64, 1179-1185. | 0.7 | 18 |
| 65 | Operationalisation of the European Protocol for Autism Prevalence (EPAP) for Autism Spectrum Disorder Prevalence Measurement in Ireland. Journal of Autism and Developmental Disorders, 2016, 46, 3054-3067. | 1.7 | 35 |
| 66 | Monitoring Huntington's Disease Mortality across a 30-Year Period: Geographic and Temporal Patterns. Neuroepidemiology, 2016, 47, 155-163. | 1.1 | 6 |
| 67 | Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. European Journal of Health Economics, 2016, 17, 43-52. | 1.4 | 35 |
| 68 | Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. European Journal of Health Economics, 2016, 17, 89-98. | 1.4 | 41 |
| 69 | Bortezomib for the treatment of acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs, 2016, 4, 775-780. | 0.5 | 1 |
| 70 | Modified checklist for autism in toddlers cross-cultural adaptation for Argentina. International Journal of Developmental Disabilities, 2016, 62, 117-123. | 1.3 | 12 |
| 71 | Consensus on the criteria needed for creating a rare-disease patient registry. A Delphi study. Journal of Public Health, 2016, 38, e178-e186. | 1.0 | 11 |
| 72 | Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. European Journal of Human Genetics, 2016, 24, 1248-1254. | 1.4 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Fragile X syndrome: economic burden and healthâ€related quality of life of patients and caregivers in France. Journal of Intellectual Disability Research, 2015, 59, 1108-1120. | 1.2 | 18 |
| 74 | Fish consumption patterns and hair mercury levels in children and their mothers in 17 EU countries. Environmental Research, 2015, 141, 58-68. | 3.7 | 107 |
| 75 | National Registries of Rare Diseases in Europe: An Overview of the Current Situation and Experiences. Public Health Genomics, 2015, 18, 20-25. | 0.6 | 30 |
| 76 | The economic burden and health-related quality of life associated with systemic sclerosis in France. Scandinavian Journal of Rheumatology, 2015, 44, 238-246. | 0.6 | 37 |
| 77 | The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations. Human Mutation, 2015, 36, 395-402. | 1.1 | 507 |
| 78 | A pilot study on the feasibility of European harmonized human biomonitoring: Strategies towards a common approach, challenges and opportunities. Environmental Research, 2015, 141, 3-14. | 3.7 | 33 |
| 79 | The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. European Journal of Human Genetics, 2015, 23, 1116-1123. | 1.4 | 63 |
| 80 | Recruitment procedures for descriptive socio-economic studies in rare diseases. The BURQOL-RD project. Expert Opinion on Orphan Drugs, 2015, 3, 759-765. | 0.5 | 8 |
| 81 | Identifying data sources for a national population-based registry: the experience of the Spanish Rare Diseases Registry. Public Health, 2015, 129, 271-275. | 1.4 | 11 |
| 82 | La detecciÃ³n e intervenciÃ³n tempranas en menores con trastorno del espectro autista. Siglo Cero, 2015, 46, 31. | 0.2 | 1 |
| 83 | Association of Immunological Cell Profiles with Specific Clinical Phenotypes of Scleroderma Disease. BioMed Research International, 2014, 2014, 1-8. | 0.9 | 15 |
| 84 | RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Orphanet Journal of Rare Diseases, 2014, 9, O14. | 1.2 | 1 |
| 85 | National Rare Disease Registries: overview from Spain. Orphanet Journal of Rare Diseases, 2014, 9, O8. | 1.2 | 4 |
| 86 | National rare diseases registry in Spain: pilot study of the Spanish Rare Diseases Registries Research Network (SpainRDR). Orphanet Journal of Rare Diseases, 2014, 9, P5. | 1.2 | 4 |
| 87 | The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Archives of Public Health, 2014, 72, 35. | 1.0 | 41 |
| 88 | Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid. Respiratory Research, 2014, 15, 125. | 1.4 | 38 |
| 89 | Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries. European Journal of Health Economics, 2014, 15, 433-437. | 1.4 | 7 |
| 90 | Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010. Lupus, 2014, 23, 431-435. | 0.8 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Social Economic Costs and Healthâ€Related Quality of Life in Patients With Systemic Sclerosis in Spain. Arthritis Care and Research, 2014, 66, 473-480. | 1.5 | 29 |
| 92 | RD-Connect: An Integrated Platform Connecting Databases, Registries, Biobanks and Clinical Bioinformatics for Rare Disease Research. Journal of General Internal Medicine, 2014, 29, 780-787. | 1.3 | 159 |
| 93 | Screening for autism spectrum disorders: state of the art in Europe. European Child and Adolescent Psychiatry, 2014, 23, 1005-1021. | 2.8 | 77 |
| 94 | Respiratory Diseases Registries in the National Registry of Rare Diseases. Archivos De Bronconeumologia, 2014, 50, 397-403. | 0.4 | 1 |
| 95 | Registros de enfermedades respiratorias integrados en el Registro Nacional de Enfermedades Raras. Archivos De Bronconeumologia, 2014, 50, 397-403. | 0.4 | 5 |
| 96 | The Current Situation and Needs of Rare Disease Registries in Europe. Public Health Genomics, 2013, 16, 288-298. | 0.6 | 33 |
| 97 | EUROPLAN: A Project to Support the Development of National Plans on Rare Diseases in Europe. Public Health Genomics, 2013, 16, 278-287. | 0.6 | 15 |
| 98 | The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Human Mutation, 2013, 34, 1449-1457. | 1.1 | 94 |
| 99 | Mortality of congenital osteochondrodysplasias: A nationwide registryâ€based study. American Journal of Medical Genetics, Part A, 2013, 161, 1555-1560. | 0.7 | 0 |
| 100 | Epidemiology of Hereditary Ataxias in Spain: Hospital Discharge Registry and Population-Based Mortality Study. Neuroepidemiology, 2013, 41, 13-19. | 1.1 | 6 |
| 101 | Further evidence supporting a genetic background for Paget's disease of bone in Spain. Anthropologischer Anzeiger, 2012, 69, 417-422. | 0.2 | 0 |
| 102 | EPIRARE survey on activities and needs of rare disease registries in the European Union. Orphanet Journal of Rare Diseases, 2012, 7, A22. | 1.2 | 6 |
| 103 | Costâ€effectiveness analysis of burning mouth syndrome therapy. Community Dentistry and Oral Epidemiology, 2012, 40, 185-192. | 0.9 | 13 |
| 104 | Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone, 2012, 51, 748-755. | 1.4 | 45 |
| 105 | Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy, 2012, 108, 19-26. | 1.4 | 38 |
| 106 | The need for worldwide policy and action plans for rare diseases. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 805-807. | 0.7 | 69 |
| 107 | Proteomics of toxic oil syndrome in humans: Phenotype distribution in a population of patients. Chemico-Biological Interactions, 2011, 192, 129-135. | 1.7 | 4 |
| 108 | Modified Checklist for Autism in Toddlers: Cross-Cultural Adaptation and Validation in Spain. Journal of Autism and Developmental Disorders, 2011, 41, 1342-1351. | 1.7 | 90 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Increase in motor neuron disease mortality in Spain: Temporal and geographical analysis (1990â€“2005). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 192-198. | 2.3 | 15 |
| 110 | Health Impact Assessment of Environmental Tobacco Smoke in European Children: Sudden Infant Death Syndrome and Asthma Episodes. Public Health Reports, 2010, 125, 478-487. | 1.3 | 25 |
| 111 | Rare Diseases Epidemiology Research. Advances in Experimental Medicine and Biology, 2010, 686, 17-39. | 0.8 | 60 |
| 112 | Rare Diseases â€“ Avoiding Misperceptions and Establishing Realities: The Need for Reliable Epidemiological Data. Advances in Experimental Medicine and Biology, 2010, 686, 3-14. | 0.8 | 40 |
| 113 | Patient involvement in health research: A contribution to a systematic review on the effectiveness of treatments for degenerative ataxias. Social Science and Medicine, 2009, 69, 920-925. | 1.8 | 62 |
| 114 | Cystic fibrosis mortality trends in Spain among infants and young children: 1981â€“2004. European Journal of Epidemiology, 2008, 23, 523-529. | 2.5 | 12 |
| 115 | Estimating the Burden of Disease for Autism Spectrum Disorders in Spain in 2003. Journal of Autism and Developmental Disorders, 2008, 38, 288-296. | 1.7 | 13 |
| 116 | Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model. Pharmacoepidemiology and Drug Safety, 2008, 17, 1100-1107. | 0.9 | 12 |
| 117 | Participation of eosinophils in the toxic oil syndrome. Clinical and Experimental Immunology, 2008, 82, 313-317. | 1.1 | 32 |
| 118 | High prevalence of cardiovascular risk in patients with toxic oil syndrome: A comparative study using the general Spanish population. European Journal of Internal Medicine, 2008, 19, 32-39. | 1.0 | 15 |
| 119 | Enfermedades raras. FMC Formacion Medica Continuada En Atencion Primaria, 2007, 14, 236-244. | 0.0 | 1 |
| 120 | Estimating the burden of scleroderma disease in Spain. Journal of Rheumatology, 2007, 34, 2236-42. | 1.0 | 12 |
| 121 | Genetic approaches in the understanding of Toxic Oil Syndrome. Toxicology Letters, 2006, 161, 83-88. | 0.4 | 6 |
| 122 | Environment and ChildÊ¼s Health: the INMA Spanish Study. Epidemiology, 2006, 17, S21. | 1.2 | 0 |
| 123 | Proteotyping of human haptoglobin by MALDI-TOF profiling: Phenotype distribution in a population of toxic oil syndrome patients. Proteomics, 2006, 6, S272-S281. | 1.3 | 9 |
| 124 | Child health and the environment: the INMA Spanish Study. Paediatric and Perinatal Epidemiology, 2006, 20, 403-410. | 0.8 | 106 |
| 125 | La detecciÃ³n precoz del autismo. Psychosocial Intervention, 2006, 15, . | 1.1 | 5 |
| 126 | Quality of life, disability and handicap in patients with toxic oil syndrome. Journal of Advanced Nursing, 2005, 50, 595-604. | 1.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Toxic oil syndrome: Genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice. Toxicology Letters, 2005, 159, 173-181. | 0.4 | 9 |
| 128 | Determination of protein markers in human serum: Analysis of protein expression in toxic oil syndrome studies. Proteomics, 2004, 4, 303-315. | 1.3 | 44 |
| 129 | Toxic oil syndrome: Survival in the whole cohort between 1981 and 1995. Journal of Clinical Epidemiology, 2003, 56, 701-708. | 2.4 | 28 |
| 130 | Characteristics of disability and handicap among toxic oil syndrome (TOS) cohort patients: a cross-sectional study, 17 years after the original food intoxication. Disability and Rehabilitation, 2003, 25, 1158-1167. | 0.9 | 1 |
| 131 | Neurologic outcomes of toxic oil syndrome patients 18 years after the epidemic.. Environmental Health Perspectives, 2003, 111, 1326-1334. | 2.8 | 6 |
| 132 | Neurologic Outcomes of Toxic Oil Syndrome Patients 18 Years after the Epidemic. Environmental Health Perspectives, 2003, 111, 1326-1334. | 2.8 | 10 |
| 133 | Prevalencia de factores de riesgo cardiovascular en una cohorte de afectados por el sÃ¬ndrome del aceite tÃ³xico. Medicina ClÃ¬nica, 2003, 121, 405-407. | 0.3 | 0 |
| 134 | The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge.. Environmental Health Perspectives, 2002, 110, 457-464. | 2.8 | 56 |
| 135 | On-Line HPLC-UV-mass spectrometry and tandem mass spectrometry for the rapid delineation and characterization of differences in complex mixtures: a case study using toxic oil variants. Biomedical Chromatography, 2002, 16, 311-318. | 0.8 | 4 |
| 136 | Immunoglobulin and autoantibody responses in MRL/lpr mice treated with â€˜toxic oilsâ€™. Toxicology, 2002, 178, 119-133. | 2.0 | 11 |
| 137 | Carpal tunnel syndrome. A new feature in the natural history of TOS?. European Journal of Epidemiology, 2002, 18, 983-993. | 2.5 | 7 |
| 138 | The Spanish Toxic Oil Syndrome 20 Years after Its Onset: A Multidisciplinary Review of Scientific Knowledge. Environmental Health Perspectives, 2002, 110, 457-464. | 2.8 | 86 |
| 139 | Pathology of â€œToxic Oilsâ€•and Selected Metals in the MRL/lpr Mouse. Toxicologic Pathology, 2001, 29, 630-638. | 0.9 | 5 |
| 140 | Storage time and deodorization temperature influence the formation of aniline-derived compounds in denatured rapeseed oils. Food and Chemical Toxicology, 2001, 39, 91-96. | 1.8 | 31 |
| 141 | Automated Strong Cation Exchange Extraction of Fatty Acid Esters of 3-(N-Phenylamino)-1,2-propanediol from Oil Samples for Routine Quantification by HPLC-APCI/MS/MS. Journal of Agricultural and Food Chemistry, 2001, 49, 5085-5091. | 2.4 | 7 |
| 142 | Determination of Aniline Derivatives in Oils Related to the Toxic Oil Syndrome by Atmospheric Pressure Ionization-Tandem Mass Spectrometry. Analytical Chemistry, 2001, 73, 3828-3837. | 3.2 | 22 |
| 143 | DR2 antigens are associated with severity of disease in toxic oil syndrome (TOS). Tissue Antigens, 2000, 55, 110-117. | 1.0 | 16 |
| 144 | Foreword. Human and Experimental Toxicology, 2000, 19, 155-157. | 1.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Epidemiologic Evidence for a New Class of Compounds Associated with Toxic Oil Syndrome. Epidemiology, 1999, 10, 130-134. | 1.2 | 61 |
| 146 | Late Deaths among Young Women Affected by the Toxic Oil Syndrome in Spain. Epidemiology, 1999, 10, 345. | 1.2 | 6 |
| 147 | Pentachlorophenol and Pentachloroanisole in Oil Samples Associated with the Toxic Oil Syndrome. Bulletin of Environmental Contamination and Toxicology, 1999, 62, 1-7. | 1.3 | 2 |
| 148 | Umbilical cord blood banking for unrelated transplantation. Experimental Hematology, 1999, 27, 380-385. | 0.2 | 51 |
| 149 | Rapid HPLC screening method for contaminants found in implicatedL-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. , 1998, 12, 255-261. | | 10 |
| 150 | Health Status Measurement in Toxic Oil Syndrome. Journal of Clinical Epidemiology, 1998, 51, 867-873. | 2.4 | 22 |
| 151 | Toxic oil syndrome mortality: the first 13 years. International Journal of Epidemiology, 1998, 27, 1057-1063. | 0.9 | 56 |
| 152 | Analytical Measurements of Products of Aniline and Triglycerides in Oil Samples Associated with the Toxic Oil Syndrome. Archives of Toxicology Supplement, 1997, 19, 53-64. | 0.7 | 4 |
| 153 | Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism. Toxicology, 1997, 118, 61-70. | 2.0 | 29 |
| 154 | Epidemiology of the Toxic Oil Syndrome. Archives of Toxicology Supplement, 1997, 19, 41-52. | 0.7 | 9 |
| 155 | Products of Aniline and Triglycerides in Oil Samples Associated with the Toxic Oil Syndrome. Chemical Research in Toxicology, 1996, 9, 1001-1006. | 1.7 | 21 |
| 156 | Toxic oil syndrome: Traceback of the toxic, oil and evidence for a point source epidemic. Food and Chemical Toxicology, 1996, 34, 251-257. | 1.8 | 34 |
| 157 | Immunological basis of toxic oil syndrome (TOS). Toxicology, 1994, 93, 289-299. | 2.0 | 27 |
| 158 | Factors Associated with Pathogenicity of Oils Related to the Toxic Oil Syndrome Epidemic in Spain. Epidemiology, 1994, 5, 404-409. | 1.2 | 26 |
| 159 | Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8â€“10, 1991, World Health Organization Meeting report. Seminars in Arthritis and Rheumatism, 1993, 23, 104-124. | 1.6 | 55 |
| 160 | Analysis of Polychlorinated Dioxins and Furans in Samples of the Toxic Oil Syndrome. Human and Experimental Toxicology, 1993, 12, 273-278. | 1.1 | 1 |
| 161 | Mortality among People Affected by Toxic Oil Syndrome. International Journal of Epidemiology, 1993, 22, 1077-1084. | 0.9 | 14 |
| 162 | Histologic abnormalities of large and small coronary arteries, neural structures, and the conduction system of the heart found in postmortem studies of individuals dying from the toxic oil syndrome. American Heart Journal, 1991, 121, 803-815. | 1.2 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Manufacturing processes at two French rapeseed oil companies: Possible relationships to toxic oil syndrome in Spain. Food and Chemical Toxicology, 1991, 29, 797-803. | 1.8 | 25 |
| 164 | Cardiac abnormalities in the toxic oil syndrome, with comparative observations on the eosinophilia-myalgia syndrome. Journal of the American College of Cardiology, 1991, 18, 1367-1379. | 1.2 | 15 |
| 165 | Toxic oil syndrome: A current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. Journal of the American College of Cardiology, 1991, 18, 711-717. | 1.2 | 63 |
| 166 | Synthesis of N-(5-vinyl-1,3-thiazolidin-2-ylidene)phenylamine and analysis of oils implicated in the spanish toxic oil syndrome for its presence. Food and Chemical Toxicology, 1989, 27, 159-164. | 1.8 | 12 |
| 167 | Late cases of toxic oil syndrome: Evidence that the aetiological agent persisted in oil stored for up to one year. Food and Chemical Toxicology, 1989, 27, 517-521. | 1.8 | 19 |
| 168 | CHEMICAL CORRELATES OF PATHOGENICITY OF OILS RELATED TO THE TOXIC OIL SYNDROME EPIDEMIC IN SPAIN. American Journal of Epidemiology, 1988, 127, 1210-1227. | 1.6 | 121 |
| 169 | Toxic-oil syndrome: Case reports associated with the ITH oil refinery in Sevilla. Food and Chemical Toxicology, 1987, 25, 87-90. | 1.8 | 41 |
| 170 | Compositional Analysis of Oil Samples Implicated in the Spanish Toxic Oil Syndrome. Journal of Food Science, 1987, 52, 1562-1569. | 1.5 | 32 |
| 171 | Esophagus and toxic oil syndrome. Digestive Diseases and Sciences, 1986, 31, 443-443. | 1.1 | 4 |
| 172 | Osteoarticular manifestations of exposure to toxic rape-seed oil. Arthritis and Rheumatism, 1983, 26, 1175-1176. | 6.7 | 1 |
| 173 | SPANISH TOXIC OIL AND CONGENITAL MALFORMATIONS. Lancet, The, 1983, 321, 181. | 6.3 | 2 |
| 174 | Current trends in biobanking for rare diseases: a review. Journal of Biorepository Science for Applied Medicine, 0, , 49. | 0.2 | 16 |
| 175 | The impact of toxic oil syndrome on physical and psychological health status using the HAQ and the PHQ-9 questionnaires. Quality of Life Research, 0, , . | 1.5 | 0 |